mediLexicon, Oct. 26, 2007 Synvista Therapeutics Inc. announced the publication of preclinical data demonstrating the ability of its compound, alagebrium, to reduce serum levels of advanced glycated end products and restore neuronal nitric oxide synthase activity in rats with diabetes. Dr. Pankaj J. Pasricha, of Stanford University School of Medicine, and colleagues; Prince VS Jeyabal, Raj Kumar, Pandu R. Gangula, Dr. Mary-Adelaide Micci; of UTMB, wrote the paper, which was published in the October 2007 issue of Neurogastroenterology and Motility.